OOIR: Observatory of International Research

Papers

(The TQCC of European Journal of Health Economics is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19	699
Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines	148
Historical evidence for economic effects of COVID-19	137
Do renewable energy and health expenditures improve load capacity factor in the USA and Japan? A new approach to environmental issues	90
COVID-19 and income inequality in OECD countries	84
Cost and effects of integrated care: a systematic literature review and meta-analysis	79
Are regions equal in adversity? A spatial analysis of spread and dynamics of COVID-19 in Europe	50
Comparison of ARIMA, ETS, NNAR, TBATS and hybrid models to forecast the second wave of COVID-19 hospitalizations in Italy	43
The COVID-19 crisis and telework: a research survey on experiences, expectations and hopes	39
HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies	37
An exploration of methods for obtaining 0 = dead anchors for latent scale EQ-5D-Y values	36
Estimation of the cost-effective threshold of a quality-adjusted life year in China based on the value of statistical life	34
The economic burden of obesity in Italy: a cost-of-illness study	34
More room for telemedicine after COVID-19: lessons for primary care?	33
Determinants of willingness to pay for health services: a systematic review of contingent valuation studies	32
COVID-19 and the role of inequality in French regional departments	30
Health effects from heat waves in France: an economic evaluation	26
How expensive are post-traumatic stress disorders? Estimating incremental health care and economic costs on anonymised claims data	26
EQ-5D-5L Bulgarian population norms	25
Modelling Covid-19 under uncertainty: what can we expect?	23
The “red herring” after 20 years: ageing and health care expenditures	23
Efficiency and productivity of health systems in prevention and control of non-communicable diseases in China, 2008–2015	23
The remarkably frequent use of EQ-5D in non-economic research	22
Self vs. other, child vs. adult. An experimental comparison of valuation perspectives for valuation of EQ-5D-Y-3L health states	22
General population normative data for the EQ-5D-3L in the five largest European economies	21

Impacts of air pollution on health: evidence from longitudinal cohort data of patients with cardiovascular diseases	21
Is stronger religious faith associated with a greater willingness to take the COVID-19 vaccine? Evidence from Israel and Japan	21
Discrete choice experiments to generate utility values for multi-attribute utility instruments: a systematic review of methods	21
The impact of the great economic crisis on mental health care in Italy	19
Does the universal medical insurance system reduce catastrophic health expenditure among middle-aged and elderly households in China? A longitudinal analysis	19
The effect of long-term care public benefits and insurance on informal care from outside the household: empirical evidence from Italy and Spain	19
Measuring health-related quality of life and well-being: a head-to-head psychometric comparison of the EQ-5D-5L, ReQoL-UI and ICECAP-A	19
Effect of financial inclusion on out-of-pocket health expenditure: empirics from Ghana	18
Evaluating the psychometric properties of the EQ-5D-5L and SF-6D among patients with haemophilia	18
Cost effectiveness of breast cancer screening and prevention: a systematic review with a focus on risk-adapted strategies	18
What is the best approach to adopt for identifying the domains for a new measure of health, social care and carer-related quality of life to measure quality-adjusted life years? Application to the dev	17
Economics of mental well-being: a prospective study estimating associated health care costs and sickness benefit transfers in Denmark	17
The excess economic burden of mental disorders: findings from a cross-sectional prevalence survey in Austria	17
Willingness to pay for a quality-adjusted life year: a systematic review with meta-regression	16
Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in the United Kingdom (UK) in 2018	16
Evaluation of the cost-utility of phosphate binders as a treatment option for hyperphosphatemia in chronic kidney disease patients: a systematic review and meta-analysis of the economic evaluations	16
Health state utility values by cancer stage: a systematic literature review	16
The relationship between renewable energy use and health expenditures in EU countries	16
Can the Covid19 pandemic affect the achievement of the ‘Zero Hunger’ goal? Some preliminary reflections	15
Patient-caregiver agreement and test–retest reliability of the EQ-5D-Y-3L and EQ-5D-Y-5L in paediatric patients with haematological malignancies	15
A guide to extending and implementing generalized risk-adjusted cost-effectiveness (GRACE)	15
Economic analysis of open versus laparoscopic versus robotic hepatectomy: a systematic review and meta-analysis	15
Predictors of negotiated prices for new drugs in Germany	15
Health-related quality of life in elderly people with hypertension and the estimation of minimally important difference using EQ-5D-5L in Hong Kong SAR, China	14
The Italian NHS at regional level: same in theory, different in practice	14
The impact of COVID-19 pandemic on insurance demand: the case of China	14
A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with metastatic, non-squamous non-small cell lung cancer and high PD-L1 expression in Switzerl	14
The economic burden of amyotrophic lateral sclerosis: a systematic review	13
Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland	13
Machine learning versus regression modelling in predicting individual healthcare costs from a representative sample of the nationwide claims database in France	13
Do European pharmacists really have to trespass on medicine?	13
Comparison of the three-level and the five-level versions of the EQ-5D	13
Testing measurement properties of two EQ-5D youth versions and KIDSCREEN-10 in China	13
Very high and low residual spenders in private health insurance markets: Germany, The Netherlands and the U.S. Marketplaces	13
The impact of social health insurance on rural populations	13
Value-based pricing for advanced therapy medicinal products: emerging affordability solutions	12
Income and conversion handicaps: estimating the impact of child chronic illness/disability on family income and the extra cost of child chronic illness/child disability in Ireland using a standard of	12
The cost of lost productivity due to premature mortality associated with COVID-19: a Pan-European study	12
Does socioeconomic status affect hospital utilization and health outcomes of chronic disease patients?	12
Has the development of cancer biomarkers to guide treatment improved health outcomes?	11
Work ethics, stay-at-home measures and COVID-19 diffusion	11
Coverage with evidence development schemes for medical devices in Europe: characteristics and challenges	11
Reassessing the impact of health expenditure on income growth in the face of the global sanitary crisis: the case of developing countries	11
Income level and antibiotic misuse: a systematic review and dose–response meta-analysis	11
The effect of mental and physical health problems on sickness absence	11
Cost-effectiveness of biennial screening for diabetes related retinopathy in people with type 1 and type 2 diabetes compared to annual screening	11
Should health technology assessment be more patient centric? If so, how?	11
COVID-19 health policy evaluation: integrating health and economic perspectives with a data envelopment analysis approach	11
‘Relative Consent’ or ‘Presumed Consent’? Organ donation attitudes and behaviour	10
Estimating the monetary value of health and capability well-being applying the well-being valuation approach	10

EQ-5D-5L Portuguese population norms	10
Value drivers of development stage biopharma companies	10
The economics of alternative payment models for pharmaceuticals	10
The causal impact of sugar taxes on soft drink sales: evidence from France and Hungary	10
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations	10
Cost-effectiveness of the latent tuberculosis screening program for migrants in Stockholm Region	10
The effect of alcohol tax changes on retail prices: how do on-trade alcohol retailers pass through tax changes to consumers?	10
Reliability and validity of using EQ-5D-5L among healthy and adolescents with major mental health disorders in Ethiopia	10
Whole exome sequencing in molecular diagnostics of cancer decreases over time: evidence from a cost analysis in the French setting	10
Preferences for COVID-19 epidemic control measures among French adults: a discrete choice experiment	10
Patterns of care and cost profiles of women with breast cancer in Italy: EPICOST study based on real world data	10
General practitioners’ income and activity: the impact of multi-professional group practice in France	9
Cost–utility analysis of risk-reducing strategies to prevent breast and ovarian cancer in BRCA-mutation carriers in Switzerland	9
Voluntary private health insurance, health-related behaviours and health outcomes: evidence from Russia	9
The residential healthcare for the elderly in Italy: some considerations for post-COVID-19 policies	9
Were we happy and we didn’t know it? A subjective dynamic and financial assessment pre-, during and post-COVID-19	9
The common interests of health protection and the economy: evidence from scenario calculations of COVID-19 containment policies	9
Mapping of the EORTC QLQ-C30 to EQ-5D-5L index in patients with lymphomas	9
Cost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain	9
Quantifying the economic impact of caregiving for Duchenne muscular dystrophy (DMD) in Spain	9
A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction	9
The impact of the diabetes management incentive on diabetes-related services: evidence from Ontario, Canada	9
The impact of decentralisation on the performance of health care systems: a non-linear relationship	9
Real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease	8
The impact of nurse staffing levels on nursing-sensitive patient outcomes: a multilevel regression approach	8
Comparing EQ-5D-3L and EQ-5D-5L in measuring the HRQoL burden of 4 health conditions in China	8
Evaluating the conduct and application of health utility studies: a review of critical appraisal tools and reporting checklists	8
Willingness-to-pay for cancer treatment and outcome: a systematic review	8
Business cycle and mortality in Spain	8
Economic evidence with respect to cost-effectiveness of the transitional care model among geriatric patients discharged from hospital to home: a systematic review	8
Costs and where to find them: identifying unit costs for health economic evaluations of diabetes in France, Germany and Italy	8
Cost-effectiveness of metabolic surgery for the treatment of type 2 diabetes and obesity: a systematic review of economic evaluations	8
The association between bed occupancy rates and hospital quality in the English National Health Service	8
Mapping MacNew Heart Disease Quality of Life Questionnaire onto country-specific EQ-5D-5L utility scores: a comparison of traditional regression models with a machine learning technique	8
Economic and social cost of epilepsy in Poland: 5-year analysis	8
Long-term cost of breast cancer treatment to the United States Medicare Program by stage at diagnosis	8
Cost-effectiveness of screening smokers and ex-smokers for lung cancer in the Netherlands in different age groups	8
The cost-effectiveness of unilateral cochlear implants in UK adults	7
Timing of non-pharmaceutical interventions to mitigate COVID-19 transmission and their effects on mobility: a cross-country analysis	7
Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations	7
Validation of the PAM-13 instrument in the Hungarian general population 40 years old and above	7
The effects of patient cost-sharing on health expenditure and health among older people: Heterogeneity across income groups	7
How French general practitioners respond to declining medical density: a study on prescription practices, with an insight into opioids use	7
Consideration of quality of life in the health technology assessments of rare disease treatments	7
Assessing the cost-effectiveness of COVID-19 vaccines in a low incidence and low mortality setting: the case of Thailand at start of the pandemic	7
Can drones save lives and money? An economic evaluation of airborne delivery of automated external defibrillators	7
Costs and management of patients with hemophilia A in France: the Hemraude study	7
Adjusted productivity costs of stroke by human capital and friction cost methods: a Northern Finland Birth Cohort 1966 study	6
The cost-effectiveness of transcatheter aortic valve implantation: exploring the Italian National Health System perspective and different patient risk groups	6
Canada population norms for the EQ-5D-5L	6
Lifetime cost of unilateral cochlear implants in adults: a Monte Carlo simulation	6
Does voluntary health insurance improve health and longevity? Evidence from European OECD countries	6
Inequality, public health, and COVID-19: an analysis of the Spanish case by municipalities	6
Investigating the geographic disparity in quality of care: the case of hospital readmission after acute myocardial infarction in Italy	6
Equity in healthcare utilization in Canada’s publicly funded health system: 2000–2014	6
Future medical and non-medical costs and their impact on the cost-effectiveness of life-prolonging interventions: a comparison of five European countries	6
Regional medical practice variation in high-cost healthcare services	6
Does linear equating improve prediction in mapping? Crosswalking MacNew onto EQ-5D-5L value sets	6
Modelling the cost-effectiveness of person-centred care for patients with acute coronary syndrome	6
Budget impact analysis of the use of oral and intravenous therapy regimens for the treatment of relapsed or refractory multiple myeloma in Germany	6
Cost-effectiveness of the MitraClip device in German heart failure patients with secondary mitral regurgitation	6
European union regulation of health technology assessment: what is required for it to succeed?	6
Ageing and health care expenditures: the importance of age per se, steepening of the individual-level expenditure curve, and the role of morbidity	6
Psychometric performance of proxy-reported EQ-5D youth version 5-level (EQ-5D-Y-5L) in comparison with three-level (EQ-5D-Y-3L) in children and adolescents with scoliosis	6
Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L descriptive systems and utilities in atopic dermatitis	6
Communities and testing for COVID-19	6
Time and lexicographic preferences in the valuation of EQ-5D-Y with time trade-off methodology	6
The effect of influenza and pneumococcal vaccination in the elderly on health service utilisation and costs: a claims data-based cohort study	6
Mapping PedsQL™ Generic Core Scales to EQ-5D-3L utility scores in transfusion-dependent thalassemia patients	6
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy	6
Effects of establishing a financing scheme for outpatient care on inpatient services: empirical evidence from a quasi-experiment in China	6